In recent years, treatment for non-small cell lung cancer (NSCLC) has dramatically evolved with the development of the anti-programmed death (PD-1) and anti-programmed death ligand 1 (PD-L1) checkpoint inhibitors. Here, CD274 is linked to non-small cell lung carcinoma.